WuXi AppTec

WuXi AppTec Receives 2021 Global Customer Value Leadership Award from Frost & Sullivan

Retrieved on: 
星期四, 十二月 9, 2021
WuXi AppTec, Research, Health, Growth, Disease, Wuxi, Leadership, Frost & Sullivan, Patient, CEO, Customer satisfaction, Frost, Development, AA, Contract research organization, Solution, MSCI, Fine chemical

SHANGHAI, Dec. 8, 2021 /PRNewswire/ --WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry,announced that it is a recipient of the 2021 Global CRDMO Customer Value Leadership Award from Frost & Sullivan, a global research & consulting firm that helps clients accelerate growth.

Key Points: 
  • SHANGHAI, Dec. 8, 2021 /PRNewswire/ --WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry,announced that it is a recipient of the 2021 Global CRDMO Customer Value Leadership Award from Frost & Sullivan, a global research & consulting firm that helps clients accelerate growth.
  • This marks the fifth consecutive year that WuXi AppTec has been recognized by Frost & Sullivan for its leadership and innovative services.
  • WuXi AppTec was honored with this award for providing unmatched customer value by enabling healthcare innovation through cost-effective and efficient solutions.
  • "We are honored to receive this award from Frost & Sullivan, and thank them for recognizing the value of our global platform to customers," said Dr. Ge Li, Chairman and CEO of WuXi AppTec.

Global Imaging CRO Market to Reach $9,603 Million by 2031 - ResearchAndMarkets.com

Retrieved on: 
星期一, 十一月 15, 2021
Science, Health, Clinical Trials, Research, WuXi AppTec, Quality control, Syneos Health, Industry, PET, CRO, Service, ICON, CAGR, Modality, ICON plc, IXICO, Growth, Joint application design, Research, MRI, Cros, Biotechnology, Maintenance, Magnetic resonance imaging, Parexel, Positron emission tomography, Contract, Fine chemical, Medical imaging

Service - Imaging Acquisition and Protocol Development, Application Design, Image Collection and Quality Control, Digital Image Conversion, Support and Maintenance

Key Points: 
  • Service - Imaging Acquisition and Protocol Development, Application Design, Image Collection and Quality Control, Digital Image Conversion, Support and Maintenance
    Modality - Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Other Modalities
    Application - Oncology Imaging CRO, Ophthalmology Imaging CRO, Neurology Imaging CRO, Cardiology Imaging CRO, Other Applications
    End User - Pharmaceutical Companies, Biotechnology Companies, Medical Device Manufacturers, Contract Research Organizations, Academic and Government Research Institutes, Other End Users
    Key Questions Answered in this Report:
    What is the major factor driving the growth of the global imaging CRO market?
  • What are the different types of services offered in the global imaging CRO market?
  • What are the key development strategies implemented by the key players to stand out in this global imaging CRO market?
  • How have the strategic collaborations among the key players provided a large service sector within the global imaging CRO market?

WuXi ATU Opens New Facility in Philadelphia, Tripling Testing Capacity to Support Global Customers

Retrieved on: 
星期一, 十一月 15, 2021
WuXi AppTec, TESSA, Industry, MSCI, Health, Navy Yard, Disease, Technology, AA, Senior, Growth, Wuxi, Shipyard, Development, Solution, Therapy, Contract research organization, Patient, AAV, PIDC, Fine chemical, Pharmaceutical industry

PHILADELPHIA, Nov. 15, 2021 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, announced the official opening of its advanced therapies testing facility at 400 Rouse Boulevard in Philadelphia's Navy Yard.

Key Points: 
  • PHILADELPHIA, Nov. 15, 2021 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, announced the official opening of its advanced therapies testing facility at 400 Rouse Boulevard in Philadelphia's Navy Yard.
  • The new facility, which includes 140,000 square feet laboratories, will further enhance the company's Contract Testing, Development and Manufacturing Organization (CTDMO) business model by tripling the company's previous testing capacity, meeting the increasing needs of customers in cell and gene therapy industry.
  • The new state-of the-art facility is an expansion of WuXi ATU's existing Navy Yard Campus, which opened in 2020.
  • "WuXi ATU has significant expertise in assay development, biologics safety testing, viral clearance and commercial lot release assays, and we are proud to bring that knowledge to our customers," said Dr. David Chang, Chief Executive Officer of WuXi ATU.

WuXi ATU Opens New Manufacturing Facility to Further Enhance Its CTDMO Services for Global Customers

Retrieved on: 
星期一, 十月 18, 2021
AAV, MSCI, Technology, WuXi AppTec, Solution, Philadelphia Naval Shipyard, GMP, Contract research organization, Disease, AA, Health, Patient, Development, Cell, Wuxi, TESSA, Contract, Fine chemical

WuXi ATU is a leading Contract, Testing, Development and Manufacturing Organization (CTDMO) headquartered in Philadelphia.

Key Points: 
  • WuXi ATU is a leading Contract, Testing, Development and Manufacturing Organization (CTDMO) headquartered in Philadelphia.
  • As its fourth manufacturing site worldwide, the new facility will supplement WuXi ATU's global footprint and will further join with other sites in the United States, United Kingdom and China to enable global customers with enhanced capacity and efficient services.
  • The Lin-gang facilityoffers integrated development, manufacturing, and testing services for viral vectors and cell therapies.
  • As the wholly owned subsidiary of WuXi AppTec, WuXi ATU is a Contract Testing, Development and Manufacturing Organization (CTDMO) that offers integrated platforms to transform the discovery, development, testing, manufacturing, and commercialization of cell and gene therapies.

New Study from StrategyR Highlights a $4.1 Billion Global Market for Cloud-Based Drug Discovery Platforms by 2026

Retrieved on: 
星期二, 十月 12, 2021
Cloud, Drug discovery, SAN, GIA, CAGR, COVID-19, Dassault Systèmes, Marketing, Growth, WuXi AppTec, Internet, Players, IBM, Contract, Forecasting, Accenture, SAS Institute Inc v World Programming Ltd, Intelligence, SAS Institute, Research, Wuxi, Pharmaceutical industry

SAN FRANCISCO, Oct. 12, 2021 /PRNewswire/ --A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Cloud-Based Drug Discovery Platforms - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, Oct. 12, 2021 /PRNewswire/ --A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Cloud-Based Drug Discovery Platforms - Global Market Trajectory & Analytics" .
  • Geographies:World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
  • Preview Registry
    Amid the COVID-19 crisis, the global market for Cloud-Based Drug Discovery Platforms estimated at US$2 Billion in the year 2020, is projected to reach a revised size of US$4.1 Billion by 2026, growing at a CAGR of 12.5% over the analysis period.
  • Global Industry Analysts, Inc., ( www.strategyr.com ) is a renowned market research publisher the world`s only influencer driven market research company.

Tergus Pharma Makes Key Executive Hires

Retrieved on: 
星期三, 九月 8, 2021

"James brings a track record of operational excellence," said Tergus Pharma Chairman and CEO, Dr. Vijendra Nalamothu.

Key Points: 
  • "James brings a track record of operational excellence," said Tergus Pharma Chairman and CEO, Dr. Vijendra Nalamothu.
  • "His experience building and running successful manufacturing and operations teams will take Tergus to the next level in providing excellence and rigor to our topical pharmaceutical clients."
  • Tergus Pharma is an end-to-end contract service provider for topical pharmaceutical products supporting early phase research and formulation, drug development, testing, and both clinical and commercial manufacturing at our new 100,000 sq.
  • Exclusively focused on topical development and manufacturing, Tergus brings the scientific expertise that helps our clients achieve the right balance of scientific knowhow, speed of results, and quality, warranting our company motto, "Think Topicals, Think Tergus."

Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland

Retrieved on: 
星期二, 八月 3, 2021
Other Manufacturing, Research, Manufacturing, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Life sciences, Industry economics), Companies, Bristol-Myers Squibb, Bristol Myers Squibb, WuXi AppTec, Squib

Bristol Myers Squibb (NYSE: BMY) today announced that it has completed the previously announced sale of its manufacturing facility in Couvet, Switzerland, to WuXi STA, a subsidiary of WuXi AppTec.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that it has completed the previously announced sale of its manufacturing facility in Couvet, Switzerland, to WuXi STA, a subsidiary of WuXi AppTec.
  • The divestiture is part of Bristol Myers Squibbs ongoing evolution of its manufacturing network to support its product portfolio.
  • Switzerland remains an important strategic location for the Company, and Bristol Myers Squibb expects to maintain a strong presence in the country.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook and Instagram .

WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Certificate

Retrieved on: 
星期一, 八月 2, 2021
Life sciences, Biotechnology, WuXi Biologics, Jiangnan, Yangtze River Delta, Articles, Pharmaceutical industry, Biopharmaceutical, Wuxi, Suzhou, European Medicines Agency, WuXi AppTec

SUZHOU, China, Aug. 2, 2021 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that only 13 months after receiving its first GMP certificate, it has once again received a European Medicines Agency (EMA) GMP certificate for the Biosafety Testing facility in Suzhou.

Key Points: 
  • SUZHOU, China, Aug. 2, 2021 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that only 13 months after receiving its first GMP certificate, it has once again received a European Medicines Agency (EMA) GMP certificate for the Biosafety Testing facility in Suzhou.
  • This certificate demonstrates WuXi Biologics' compliance to global cGMP biosafety testing standards and regulatory guidelines.
  • Dr. Chris Chen, CEO of WuXi Biologics, commented, "The second EMA certificate is the solid proof of our world-class quality system as well as the technology platforms utilized at our Suzhou facility.
  • WuXi Biologics Biosafety Testing team offers cell line characterization and adventitious agent testing for the QC release of cell banks, unprocessed bulk (UPB) lots and raw materials.

WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Certificate

Retrieved on: 
星期一, 八月 2, 2021
Life sciences, Biotechnology, WuXi Biologics, Jiangnan, Yangtze River Delta, Articles, Pharmaceutical industry, Biopharmaceutical, Wuxi, Suzhou, European Medicines Agency, WuXi AppTec

SUZHOU, China, Aug. 2, 2021 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that only 13 months after receiving its first GMP certificate, it has once again received a European Medicines Agency (EMA) GMP certificate for the Biosafety Testing facility in Suzhou.

Key Points: 
  • SUZHOU, China, Aug. 2, 2021 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that only 13 months after receiving its first GMP certificate, it has once again received a European Medicines Agency (EMA) GMP certificate for the Biosafety Testing facility in Suzhou.
  • This certificate demonstrates WuXi Biologics' compliance to global cGMP biosafety testing standards and regulatory guidelines.
  • Dr. Chris Chen, CEO of WuXi Biologics, commented, "The second EMA certificate is the solid proof of our world-class quality system as well as the technology platforms utilized at our Suzhou facility.
  • WuXi Biologics Biosafety Testing team offers cell line characterization and adventitious agent testing for the QC release of cell banks, unprocessed bulk (UPB) lots and raw materials.

Metrion Biosciences appoints Nick Foster as Chief Commercial Officer and Head of Global Business Development

Retrieved on: 
星期一, 七月 26, 2021
Biotechnology, Health, Science, Pharmaceutical, Research, Contract research organizations, Life sciences, WuXi AppTec, Charles River Laboratories, Articles, Industry economics)

Metrion Biosciences Limited (Metrion), the specialist ion channel contract research and drug discovery company, today announced the appointment of Nick Foster as Chief Commercial Officer and Head of Global Business Development, to support the broadening of Metrions international customer base and facilitate entry into new territories.

Key Points: 
  • Metrion Biosciences Limited (Metrion), the specialist ion channel contract research and drug discovery company, today announced the appointment of Nick Foster as Chief Commercial Officer and Head of Global Business Development, to support the broadening of Metrions international customer base and facilitate entry into new territories.
  • Following his early career as a laboratory scientist, Nick moved into business development, holding positions as Associate Director, Business Development Europe for BioFocus Limited (now Charles River Laboratories), Head of Commercial Operations at Optibrium Limited, and Director, Business Development for WuXi AppTec.
  • Dr Andrew Southan, Chief Executive Officer of Metrion Biosciences, said: I am very pleased to welcome Nick to Metrions senior management team.
  • Nick Foster Chief Commercial Officer, Metrion BIosciences, commented: I am delighted to be joining Metrion at this exciting time of expansion for the company.